硫利达嗪需钙内流诱导MLL-AF6重排AML细胞死亡
研究对1280种化合物进行高通量药物筛选,发现硫利达嗪(TDZ)对t(6;11)(q27;q23) MLL-AF6重排AML具有高度选择性。TDZ在体外诱导细胞死亡并不可逆地丧失克隆形成能力,机制涉及细胞骨架重塑导致Ca2+内流、线粒体去极化引发凋亡;体内实验证实其毒性,并开发出神经安定副作用更低的新型类似物。
要点
- TDZ对t(6;11) MLL-AF6 AML具有高度选择性,该亚型生存率低于20%。
- TDZ通过细胞骨架重塑引起Ca2+内流,经线粒体去极化触发凋亡。
- 新型TDZ类似物保留抗白血病效果且降低神经安定副作用。
核心结论
- TDZ需钙内流才能选择性诱导MLL-AF6重排AML细胞死亡,新型类似物可降低神经安定副作用。
研究设计与样本
- 对1280种化合物进行高通量药物筛选,并在体外和体内验证TDZ对t(6;11)AML的作用。
主要发现
- TDZ对t(6;11)(q27;q23) MLL-AF6重排AML高度选择性,该亚型生存率低于20%。
- TDZ体外诱导细胞死亡并使白血病细胞克隆形成能力不可逆丧失。
- TDZ引起细胞骨架重塑导致Ca2+内流,线粒体去极化触发凋亡,该现象在t(6;11)AML中选择性发生。
- 体内实验证实TDZ对t(6;11)AML的毒性,新型TDZ类似物减少白血病且神经安定作用降低。
临床怎么用
- TDZ及其类似物可能成为t(6;11) MLL-AF6重排AML的靶向治疗候选,需进一步临床试验验证。
局限性
- 研究结果需在进一步临床试验中证实TDZ靶向MLL-AF6 AML的获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In pediatric acute myeloid leukemia (AML), intensive chemotherapy and allogeneic hematopoietic stem cell transplantation are the cornerstones of treatment in high-risk cases, with severe late effects and a still high risk of disease recurrence as the main drawbacks. The identification of targeted, more effective, safer drugs is thus desirable. We performed a high-throughput drug-screening assay of 1280 compounds and identified thioridazine (TDZ), a drug that was highly selective for the t(6;11)(q27;q23) MLL-AF6 (6;11)AML rearrangement, which mediates a dramatically poor (below 20%) survival rate. TDZ induced cell death and irreversible progress toward the loss of leukemia cell clonogenic capacity in vitro. Thus, we explored its mechanism of action and found a profound cytoskeletal remodeling of blast cells that led to Ca2+ influx, triggering apoptosis through mitochondrial depolarization, confirming that this latter phenomenon occurs selectively in t(6;11)AML, for which AF6 does not work as a cytoskeletal regulator, because it is sequestered into the nucleus by the fusion gene. We confirmed TDZ-mediated t(6;11)AML toxicity in vivo and enhanced the drug's safety by developing novel TDZ analogues that exerted the same effect on leukemia reduction, but with lowered neuroleptic effects in vivo. Overall, these results refine the MLL-AF6 AML leukemogenic mechanism and suggest that the benefits of targeting it be corroborated in further clinical trials.
引用
- Tregnago C, Da Ros A, Porcù E, et al. Thioridazine requires calcium influx to induce MLL-AF6-rearranged AML cell death. Blood Adv. 2020. PMID: 32931582. doi:10.1182/bloodadvances.2020002001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。